Maravai LifeSciences Holdings Inc (MRVI) Q3 2024 Earnings Call Highlights: Navigating ...

In Q4, the firm expects to fulfill $14 million of commitments. Factors influencing NAP revenue decline are project delays to 2025 and a weaker market. The acquisition for 2025 brings low single-digit million revenue and Q4 focuses on discovery business rates and potential drop-in orders.